I question how a Neurologist can even make that assumption (copaxone failure) when the drug only has a 30% chance of delaying progression. That's a pretty low number.

Plus, it's not the number of lesions you have....it's where they're located that matters.

I am getting pretty disgusted at the Neurologists and big pharma who have a financial stake in the approval of MS treatments. It's almost like they don't want us to ever be "totally OK"......because that would mean a loss of revenue for them.